|
Mar 13
|
Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?
|
|
Mar 12
|
Arvinas' Vepdegestrant Likely to Have 'Restricted Label' in Breast Cancer, Wedbush Says
|
|
Mar 12
|
ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study
|
|
Mar 11
|
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
|
|
Mar 11
|
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
|
|
Mar 11
|
Arvinas gets positive breast cancer data, but finds differentiation a hard sell
|
|
Mar 11
|
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
|
|
Feb 21
|
Arvinas (NASDAQ:ARVN) shareholders have endured a 72% loss from investing in the stock three years ago
|
|
Jan 21
|
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
|
|
Jul 30
|
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
|
|
Jul 30
|
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
|
Jun 27
|
Arvinas, Inc. (ARVN): Why Did Analysts Give This Small-Cap Stock a Strong Buy Rating?
|
|
Jun 24
|
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
|
|
Jun 24
|
Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?
|
|
Jun 21
|
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
|
|
Jun 17
|
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
|
|
May 23
|
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
|
|
May 23
|
It Looks Like Arvinas, Inc.'s (NASDAQ:ARVN) CEO May Expect Their Salary To Be Put Under The Microscope
|
|
May 16
|
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
|
|
May 11
|
Arvinas, Inc. (NASDAQ:ARVN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
|